Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1400ANCILLARY||SWOG||Ancillary Study to Evaluate Patient and Physician Attitudes; Knowledge; and Expectations Related to Return of Genomic Results in Cancer in the SWOG 1400 (S1400) Clinical Trial||Adult CIRB - Late Phase Emphasis|
|9149||ETCTN||Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors||Adult CIRB - Late Phase Emphasis||Available to Open|
|LungMAP||SWOG||A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)||Adult CIRB - Late Phase Emphasis||Available to Open|
|AALL1331||COG||Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467; NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL): A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|RTOG-0815||RTOG||A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|10129||ETCTN||A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|CALGB-100104||CALGB||A Phase III Randomized; Double-Blind Study of Maintenance Therapy with CC-5013 (NSC #703813; IND#70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GY001||NRG||A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women with Recurrent; Clear Cell Carcinoma of the Ovary; Fallopian Tube; or Peritoneum||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GY018||NRG||A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|AOST1421||COG||A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab; NSC# 764038; IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma||Pediatric CIRB||Available to Open|